Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Neonc Technologies, Inc.
National Cancer Institute (NCI)
University of Nebraska
Eli Lilly and Company
ITM Solucin GmbH
National Cancer Institute (NCI)
University of Southern California
Eli Lilly and Company
RefleXion Medical
Eli Lilly and Company
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
The New York Proton Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Masonic Cancer Center, University of Minnesota
Avera McKennan Hospital & University Health Center
Mayo Clinic
Technische Universität Dresden
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Illinois at Chicago
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Memorial Sloan Kettering Cancer Center
Children's Oncology Group
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Vanderbilt University
National Cancer Institute (NCI)
European Organisation for Research and Treatment of Cancer - EORTC
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Dana-Farber Cancer Institute